N-acetylcysteine does not prevent contrast-induced nephropathy after cardiac catheterization in patients with diabetes mellitus and chronic kidney disease: A randomized clinical trial

Trials

Volumn 10, Issue , 2009, Pages

  Amini, Manouchehr ^a   Salarifar, Mojtaba ^b   Amirbaigloo, Alireza ^a   Masoudkabir, Farzad ^c   Esfahani, Fatemeh ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; CONTRAST MEDIUM; CREATINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IODIXANOL; IOHEXOL; MEGLUMINE DIATRIZOATE; MEGLUMINE DIATRIZOATE PLUS SODIUM DIATRIZOATE; PLACEBO; CREATININE; SCAVENGER;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONTRAST INDUCED NEPHROPATHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; FEMALE; HEART CATHETERIZATION; HUMAN; HYDRATION; MAJOR CLINICAL STUDY; MALE; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; UREA NITROGEN BLOOD LEVEL; AGED; BLOOD; CHEMICALLY INDUCED DISORDER; CHRONIC KIDNEY FAILURE; INCIDENCE; KIDNEY DISEASE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PROSPECTIVE STUDY; RISK FACTOR;

ACETYLCYSTEINE; ADMINISTRATION, ORAL; AGED; CONTRAST MEDIA; CORONARY ANGIOGRAPHY; CREATININE; DIABETES MELLITUS; FEMALE; FREE RADICAL SCAVENGERS; HEART CATHETERIZATION; HUMANS; INCIDENCE; KIDNEY DISEASES; MALE; MIDDLE AGED; PLACEBOS; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS;

EID: 68349100010     PISSN: 17456215     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-10-45     Document Type: Article

References (42)

1. Hou SH Bushinsky DA Wish JB Cohen JJ Harrington JT Hospital-acquired renal insufficiency: A prospective study Am J Med 1983, 74:243-248. 10.1016/0002-9343(83)90618-6 6824004
2. Murphy SW Barrett BJ Parfrey PS Contrast nephropathy J Am Soc Nephrol 2000, 11:177-182. 10616853
3. Parfrey PS Griffiths SM Barrett BJ Paul MD Genge M Withers J Farid N McManamon PJ Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both. A prospective controlled study N Engl J Med 1989, 320:143-149. 2643041
4. Rich MW Crecelius CA Incidence, risk factors, and clinical course of acute renal insufficiency after cardiac catheterization in patients 70 years of age or older. A prospective study Arch Intern Med 1990, 150:1237-1242. 10.1001/archinte.150.6.1237 2353856
5. McCullough PA Wolyn R Rocher LL Levin RN O'Neill WW Acute renal failure after coronary intervention: Incidence, risk factors, and relationship to mortality Am J Med 1997, 103:368-375. 10.1016/S0002-9343(97)00150-2 9375704
6. Gruberg L Mintz GS Mehran R Gangas G Lansky AJ Kent KM Pichard AD Satler LF Leon MB The prognostic implications of further renal function deterioration within 48 h of interventional coronary procedures in patients with pre-existent chronic renal insufficiency J Am Coll Cardiol 2000, 36:1542-1548. 10.1016/S0735-1097(00)00917-7 11079656
7. Levy EM Viscoli CM Horwitz RI The effect of acute renal failure on mortality. A cohort analysis JAMA 1996, 275:1489-1494. http:// jama.ama-assn.org/cgi/content/short/275/19/1489 8622223 10.1001/ jama.275.19.1489
8. Rihal CS Textor SC Grill DE Berger PB Ting HH Best PJ Singh M Bell MR Barsness GW Mathew V et al Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention Circulation 2002, 105:2259-2264. 10.1161/01.CIR.0000016043.87291.33 12010907
9. Chen SL Zhang J Yei F Zhu Z Liu Z Lin S Chu J Yan J Zhang R Kwan TW Clinical outcomes of contrast-induced nephropathy in patients undergoing percutaneous coronary intervention: A prospective, multicenter, randomized study to analyze the effect of hydration and acetylcysteine Int J Cardiol 2008, 126:407-413. 10.1016/j.ijcard.2007.05.004 17651830
10. Solomon R Deray G How to prevent contrast-induced nephropathy and manage risk patients: Practical recommendations Kidney Int Suppl 2006:S51-53. 10.1038/sj.ki.5000375 16612402
11. Tepel M Giet van der M Schwarzfeld C Laufer U Liermann D Zidek W Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine N Engl J Med 2000, 343:180-184. 10.1056/ NEJM200007203430304 10900277
12. Efrati S Dishy V Averbukh M Blatt A Krakover R Weisgarten J Morrow JD Stein MC Golik A The effect of N-acetylcysteine on renal function, nitric oxide, and oxidative stress after angiography Kidney Int 2003, 64:2182-2187. 10.1046/j.1523-1755.2003.00322.x 14633141
13. Briguori C Manganelli F Scarpato P Elia PP Golia B Riviezzo G Lepore S Librera M Villari B Colombo A Ricciardelli B Acetylcysteine and contrast agent-associated nephrotoxicity J Am Coll Cardiol 2002, 40:298-303. 10.1016/S0735-1097(02)01958-7 12106935
14. Recio-Mayoral A Chaparro M Prado B Cozar R Mendez I Banerjee D Kaski JC Cubero J Cruz JM The reno-protective effect of hydration with sodium bicarbonate plus N-acetylcysteine in patients undergoing emergency percutaneous coronary intervention: The RENO Study J Am Coll Cardiol 2007, 49:1283-1288. 10.1016/j.jacc.2006.11.034 17394959
15. Carbonell N Blasco M Sanjuan R Perez-Sancho E Sanchis J Insa L Bodi V Nunez J Garcia-Ramon R Miguel A Intravenous N-acetylcysteine for preventing contrast-induced nephropathy: A randomised trial Int J Cardiol 2007, 115:57-62. 10.1016/j.ijcard.2006.04.023 16814414
16. Baker CS Wragg A Kumar S De Palma R Baker LR Knight CJ A rapid protocol for the prevention of contrast-induced renal dysfunction: The RAPPID study J Am Coll Cardiol 2003, 41:2114-2118. 10.1016/ S0735-1097(03)00487-X 12821233
17. Durham JD Caputo C Dokko J Zaharakis T Pahlavan M Keltz J Dutka P Marzo K Maesaka JK Fishbane S A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography Kidney Int 2002, 62:2202-2207. 10.1046/j.1523-1755.2002.00673.x 12427146
18. Diaz-Sandoval LJ Kosowsky BD Losordo DW Acetylcysteine to prevent angiography-related renal tissue injury (the APART trial) Am J Cardiol 2002, 89:356-358. 10.1016/S0002-9149(01)02243-3 11809444
19. Shyu KG Cheng JJ Kuan P Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure J Am Coll Cardiol 2002, 40:1383-1388. 10.1016/ S0735-1097(02)02308-2 12392825
20. Goldenberg I Shechter M Matetzky S Jonas M Adam M Pres H Elian D Agranat O Schwammenthal E Guetta V Oral acetylcysteine as an adjunct to saline hydration for the prevention of contrast-induced nephropathy following coronary angiography. A randomized controlled trial and review of the current literature Eur Heart J 2004, 25:212-218. 10.1016/ j.ehj.2003.11.011 14972421
21. Kay J Chow WH Chan TM Lo SK Kwok OH Yip A Fan K Lee CH Lam WF Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: A randomized controlled trial JAMA 2003, 289:553-558. 10.1001/jama.289.5.553 12578487
22. Seyon RA Jensen LA Ferguson IA Williams RG Efficacy of N-acetylcysteine and hydration versus placebo and hydration in decreasing contrast-induced renal dysfunction in patients undergoing coronary angiography with or without concomitant percutaneous coronary intervention Heart Lung 2007, 36:195-204. 10.1016/j.hrtlng.2006.08.004 17509426
23. Sandhu C Belli AM Oliveira DB The role of N-acetylcysteine in the prevention of contrast-induced nephrotoxicity Cardiovasc Intervent Radiol 2006, 29:344-347. 10.1007/s00270-005-0127-8 16502177
24. Gomes VO Poli de Figueredo CE Caramori P Lasevitch R Bodanese LC Araujo A Roedel AP Caramori AP Brito FS Jr Bezerra HG et al N-acetylcysteine does not prevent contrast induced nephropathy after cardiac catheterisation with an ionic low osmolality contrast medium: A multicentre clinical trial Heart 2005, 91:774-778. 1768952 15894775 10.1136/hrt.2004.039636
25. Marenzi G Assanelli E Marana I Lauri G Campodonico J Grazi M De Metrio M Galli S Fabbiocchi F Montorsi P et al N-acetylcysteine and contrast-induced nephropathy in primary angioplasty N Engl J Med 2006, 354:2773-2782. 10.1056/NEJMoa054209 16807414
26. Coyle LC Rodriguez A Jeschke RE Simon-Lee A Abbott KC Taylor AJ Acetylcysteine In Diabetes (AID): A randomized study of acetylcysteine for the prevention of contrast nephropathy in diabetics Am Heart J 2006, 151:1032.e9-1032.e12. 16644332 10.1016/j.ahj.2006.02.002
27. Nallamothu BK Shojania KG Saint S Hofer TP Humes HD Moscucci M Bates ER Is acetylcysteine effective in preventing contrast-related nephropathy? A meta-analysis Am J Med 2004, 117:938-947. 10.1016/j.amjmed.2004.06.046 15629733
28. Isenbarger DW Kent SM O'Malley PG Meta-analysis of randomized clinical trials on the usefulness of acetylcysteine for prevention of contrast nephropathy Am J Cardiol 2003, 92:1454-1458. 10.1016/ j.amjcard.2003.08.059 14675586
29. Birck R Krzossok S Markowetz F Schnulle P Woude van der FJ Braun C Acetylcysteine for prevention of contrast nephropathy: Meta-analysis Lancet 2003, 362:598-603. 10.1016/S0140-6736(03)14189-X 12944058
30. Bagshaw SM Ghali WA Acetylcysteine for prevention of contrast-induced nephropathy after intravascular angiography: A systematic review and meta-analysis BMC Med 2004, 2:38. 526263 15500690 10.1186/1741-7015-2-38
31. Kshirsagar AV Poole C Mottl A Shoham D Franceschini N Tudor G Agrawal M Denu-Ciocca C Magnus Ohman E Finn WF N-acetylcysteine for the prevention of radiocontrast induced nephropathy: A meta-analysis of prospective controlled trials J Am Soc Nephrol 2004, 15:761-769. 10.1097/ 01.ASN.0000116241.47678.49 14978179
32. Pannu N Manns B Lee H Tonelli M Systematic review of the impact of N-acetylcysteine on contrast nephropathy Kidney Int 2004, 65:1366-1374. 10.1111/j.1523-1755.2004.00516.x 15086476
33. Liu R Nair D Ix J Moore DH Bent S N-acetylcysteine for the prevention of contrast-induced nephropathy. A systematic review and meta-analysis J Gen Intern Med 2005, 20:193-200. 1490056 15836554 10.1111/ j.1525-1497.2005.30323.x
34. Duong MH MacKenzie TA Malenka DJ N-acetylcysteine prophylaxis significantly reduces the risk of radiocontrast-induced nephropathy: comprehensive meta-analysis Catheter Cardiovasc Interv 2005, 64:471-479. 10.1002/ccd.20342 15789388
35. Zagler A Azadpour M Mercado C Hennekens CH N-acetylcysteine and contrast-induced nephropathy: A meta-analysis of 13 randomized trials Am Heart J 2006, 151:140-145. 10.1016/j.ahj.2005.01.055 16368307
36. Gonzales DA Norsworthy KJ Kern SJ Banks S Sieving PC Star RA Natanson C Danner RL A meta-analysis of N-acetylcysteine in contrast-induced nephrotoxicity: Unsupervised clustering to resolve heterogeneity BMC Med 2007, 5:32. 2200657 18001477 10.1186/1741-7015-5-32
37. Kelly AM Dwamena B Cronin P Bernstein SJ Carlos RC Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy Ann Intern Med 2008, 148:284-294. http://www.annals.org/cgi/pmidlookup?view= long&pmid=18283206 18283206
38. Cockcroft DW Gault MH Prediction of creatinine clearance from serum creatinine Nephron 1976, 16:31-41. 10.1159/000180580 1244564
39. Fishbane S Durham JH Marzo K Rudnick M N-acetylcysteine in the prevention of radiocontrast-induced nephropathy J Am Soc Nephrol 2004, 15:251-260. 10.1097/01.ASN.0000107562.68920.92 14747371
40. Aspelin P Aubry P Fransson SG Strasser R Willenbrock R Berg KJ Nephrotoxic effects in high-risk patients undergoing angiography N Engl J Med 2003, 348:491-499. 10.1056/NEJMoa021833 12571256
41. Tumlin JA Wang A Murray PT Mathur VS Fenoldopam mesylate blocks reductions in renal plasma flow after radiocontrast dye infusion: A pilot trial in the prevention of contrast nephropathy Am Heart J 2002, 143:894-903. 10.1067/mhj.2002.122118 12040355
42. Rashid ST Salman M Myint F Baker DM Agarwal S Sweny P Hamilton G Prevention of contrast-induced nephropathy in vascular patients undergoing angiography: A randomized controlled trial of intravenous N-acetylcysteine J Vasc Surg 2004, 40:1136-1141. 10.1016/ j.jvs.2004.09.026 15622367